Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Amanda Marley-Clarke who wrote (2)	3/2/1998 2:46:00 PM
From: Jeffrey L. Henken	Read Replies (2) \| Respond to of 2887

The company has made lots of progress lately that simply is not reflected in the stock price. I checked out the web site that you suggested and I suppose that even though they are not an IPO there is a few references to additional financing there at the site. ABMI is already working on some arrangements in that area. Over 25 patents. The only all silicone line of catheters in the business. No allergic reaction to silicone! Many other advantages over latex americanbiomed.com Many patents pending along with additional FDA approvals expected. Exciting new products in the R&D pipeline like the Guidewire Microfilter, Stents and the 7Fr OmniCath-Coronary Version. The market is growing for the company's products and I am confident that ABMI will be ramping up towards real sucess soon. Regards, Jeff

To: Amanda Marley-Clarke who wrote (2)	3/2/1998 7:32:00 PM
From: Aishwarya	Read Replies (1) \| Respond to of 2887

Here is some research in a capsule for New Investors American BioMed Inc.is engaged in the development, manufacture and marketing of next generation minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced technology. OmniStent(tm), which incorporates the company's (U.S. and European) patented "endless loop" process, offers the physician a choice in configurations and more options (including bifurcations) than any other stent in this 2-billion $ market. OmniCath(r) is a directional atherectomy catheter that employs deflecting nontraumatizing wires to anchor the cutting window at the atherectomy site. Directional atherectomy is used as an alternative and adjunct to angioplasty and stent procedures intended to treat peripheral vascular disease. Other devices such as unique silicone catheters as well as spinal dissectors are also marketed by the company. Management of the company has undertaken efforts to identify healthcare companies with similar technologies to its own or companies seeking new proprietary products to strengthen their existing market position. The change in management has reflected an overall enthusiasm to sell their products aggressively like it has never ben done before. They should get the benefit of doubt for their actions and this stock is poised to move from here or get interest from other companies for takeover/partnership perspective. Their strategy is directed toward the formation of strategic alliances, joint venture arrangements, licensing and distribution agreements, and research and development agreements/projects. An integral part of this strategy is to aggressively pursue the sale of ancillary technologies which will enable the company to focus its resources exclusively on its core technologies and continued commercialization of its all silicone balloon catheter products. According to industry sources, the world wide market for their products are estimated at approximately 2 billion dollars plus. The company anticipates it can initially penetrate and achieve a decent market share and capture 25% of this market with a strong strategic alliance partner. To get here they have formed alliances with a lot of distributors and resellers lately and this is viewed as a positive. What the ISO 9000 means to all of us on this thread. ABMI is conforming to international standards and they can potentially manufacture the likes of cathers and stents etc,. on an OEM scale for other manufacturers. This is an ideal way to keep operations lean as they do not increase their stock on these products. Instead the devices are manufactured after orders are booked. This has many advantages that they will not have to spend a dollar till it is absolutely necessary and they in turn will benefit from huge sales to other companies in the similar technologies. Now it is a lot cheaper for other companies to buy through another manufacturer as it is a very costly process to establish manufacturing facilities and employ people and thus overheads increase. Regards, Sri